In 2023, Global Healthcare will continue to be deeply involved in the healthcare sector, forge ahead, overcome difficulties, and continue to repay society and shareholders with steady growth performance: achieved total revenue of RMB 13.650 billion for the whole year, an increase of 13.1% over the same period of the previous year. Among them, the healthcare business achieved revenue of RMB 7.833 billion, an increase of 22.9% over the same period of the previous year, and its share of total revenue has increased to 57.4%; Net profit of RMB 2,199 billion, an increase of 5.4% over the same period last year. $454 million, an increase of 20.6% over the same period of the previous year; net profit attributable to common equity holders was RMB 2,021 million, up 7.0% from the same period of the previous year, of which the healthcare business contributed RMB 365 million, an increase of 45.8% over the same period of the previous year; the return on total assets (ROA) was 2.80%, and the return on equity (ROE) attributable to common stock holders was 13.63%, and earnings indicators and asset conditions remained steady and excellent. It is proposed to distribute a dividend of HK$0.35 per share in 2023, with a dividend payout ratio of 30%.
The development trend of comprehensive medical care continues to improve
As of December 31, 2023, Global Healthcare has combined a total of 14,353 beds (not including more than 4,000 beds in internal planning and construction). In 2023, the comprehensive medical business sector strengthened internal performance and improved quality and efficiency, and the development trend continued to improve: annual contribution report revenue of RMB 7.634 billion, an increase of 20.5% over the same period of the previous year; total net profit of RMB 421 million, an increase of 14.7% over the same period of the previous year; the comprehensive net profit margin of medical institutions was 5.10%, up 0.16 percentage points from the same period last year.
Accelerate the deployment of specialty and health industries
In 2023, the company simultaneously began connotative development and epitaxial expansion in this sector to accelerate the pace of business promotion and mergers and acquisitions: total annual reporting revenue of RMB 244 million, an increase of 190.7% over the same period of the previous year; total net profit of RMB 32 million was realized, an increase of 271.8% over the same period last year.
● The specialist medical layout has been further consolidated and improved
Nephrology: In 2023, Global Healthcare wholly-owned the nephrology business platform “Global Yuegu”, empowering 21 hospitals internally to promote a full-course nephropathy management model, achieving revenue of RMB 270 million in the comprehensive medical business sector, an increase of 18.9% over the previous year; it has completed the merger and acquisition of Bishi University (Chengdu) Nephrology Specialist Hospital and Haiyang Senzhikang Hospital (Hemodialysis Center), and continues to promote mergers and acquisitions of other specialty hospitals and hemodialysis centers.
Oncology: In 2023, Global Healthcare and Maisheng Medical Group, a leading international miniaturized proton diagnosis and treatment equipment company, jointly established the precision oncology service company “Global Maisheng” as the only platform for cancer radiotherapy services between the two sides, to accelerate the construction of a leading domestic accurate cancer diagnosis and treatment business system and intelligent accurate cancer diagnosis and treatment service platform, and achieve revenue of RMB 159 million in the comprehensive medical business sector, an increase of 14.8% over the same period last year; expand the scale of the chain business through external investment/construction to promote standardization and collaboration in oncology specialists , Efficient development.
● Equipment full-cycle management business to achieve energy level leapfrogging
While serving internal and external hospital customers, Global Healthcare has successfully merged and acquired Casixuanda Medical Technology Wuxi Co., Ltd. (hereinafter referred to as “Casixuanda”) and Shandong Tuozhuang Medical Technology Co., Ltd., focusing on deep integration in strategy, market, technology, management, talent, culture, etc., to establish the core capabilities of “efficient operation+specialized technology” to accelerate the construction of a leading brand in the central enterprise industry. Currently, the business segment has served 720 customers across the country, with a total asset management scale of nearly RMB 20 billion. It contributed to reporting revenue of RMB 243 million for the full year of 2023, an increase of 241% over the same period last year; net profit of RMB 35 million, an increase of 208% over the same period last year.
●Accelerate the transformation layout of digital industrialization in the medical field
At the beginning of 2024, Global Healthcare completed the merger and acquisition of Shandong Qingniao Softcom Information Technology Co., Ltd., a leading domestic smart health and pension enterprise. The two sides will actively explore the development model of integrated medical care services integrating digital technology with medical rehabilitation, disease prevention, and health and old-age care, build a smart medical care service system integrating home, community, and institution. While empowering the high-quality development of internal hospital business, it will become the leading domestic intelligent home health care brand. It will become an independent industry line under the company that can release greater value.
Steady growth in financial business
2023 is still a competitive and challenging year for the financial leasing industry. Global Healthcare adheres to its functional position based on serving the real economy and the development of the main business, focusing on strengthening the development of high-quality customers and continuously improving the level of financing management. Under the adverse effects of rising overseas financing costs due to the Federal Reserve's interest rate hike, operating efficiency still achieved steady growth: total financial business revenue of RMB 5.882 billion for the whole year, an increase of 2.8% over the same period last year; achieved net profit of RMB 1,745 billion, an increase of 2.1% over the same period last year. While maintaining steady operations, the company continues to strengthen asset management, and asset quality has remained good: as of December 31, 2023, the company's net interest-bearing assets reached RMB 67.349 billion, up 3.2% from the beginning of the year; the non-performing asset ratio was 0.98%, the 30-day overdue rate was 0.89%, and the provision coverage rate was 284.55%.
Furthermore, while building a model for high-quality development of listed healthcare central enterprises and serving the “Healthy China” strategy, Global Healthcare also pays great attention to ESG practices and integrates global sustainable development goals into the company's daily management and operation. In 2023, Global Healthcare ranked 62nd in the “China ESG Listed Companies Pioneer 100” list, and actively became one of the first batch of ISSB International Sustainable Development Accounting Compliance Advanced Study Partners in China, actively fulfilling social responsibilities through practical actions and promoting the leapfrog growth of listed companies with leading overall value.
2024 outlook
2024 will be an important year for Global Healthcare to enhance its ability to create corporate value and strengthen and improve the healthcare industry group. The company is committed to developing into a healthcare enterprise with financial service capabilities, specialty medical characteristics and differentiated industry-side business advantages, and gradually fully unleash the value of its various business segments and assets, and relentlessly advance towards the vision of serving “healthy China” and “becoming a trustworthy world-class healthcare enterprise”, and creating greater value returns for all shareholders.